首页> 美国卫生研究院文献>Journal of Clinical and Diagnostic Research : JCDR >Efficacy of Rebamipide and Levamisole in the Treatment of Patients with Recurrent Aphthous Ulcer - A Comparative Study
【2h】

Efficacy of Rebamipide and Levamisole in the Treatment of Patients with Recurrent Aphthous Ulcer - A Comparative Study

机译:瑞巴派特和左旋咪唑治疗复发性口疮的疗效比较研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Context (Background): Recurrent aphthous stomatitis is an inflammatory condition of unknown aetiology characterized by painful recurrent, single or multiple ulcerations of the oral mucosa.>Aims: To compare the efficacy of rebamipide, a gastro-protective agent and levamisole, an immunomodulating agent in the treatment of recurrent aphthous stomatitis.>Materials and Methods: Hundred patients diagnosed with recurrent aphthous stomatitis were enrolled in the study. Fifty patients were assigned randomly to each of the two treatment groups. After the clinical diagnosis and ulcer measurement, a subjective evaluation of symptoms was done for each subject. Both the drugs were given orally at specified intervals. Ulcer measurements and subjective evaluations were made at day one.>Statistical Analysis: Analysis was done using various test like Mann Whitney and t-test.>Results and Conclusion: The overall results showed mean number of episodes whose values were not statistically significant (p=0.43), neither were the mean number of ulcers (p=0.75), or values for mean size of ulcers (p=0.91). However, the overall results suggested that efficacy of rebamipide is almost same as that of the efficacy of previously proved drug levamisole. The current study with a three months follow up, including patients with high scores of pain, aphthae count, ulcer size and frequency of occurrence showed better results in both the study groups. However, rebamipide is suggested to be well tolerated and may therefore be useful in the treatment and prevention of frequently recurrent aphthous ulcers not restricted to Behcet’s disease.
机译:>背景(背景):复发性口疮性口炎是一种病因不明的炎症性疾病,其特征是口腔粘膜复发性,单个或多次溃疡性疼痛。>目的:瑞巴派特,一种胃保护剂和左旋咪唑,一种免疫调节剂,用于治疗复发性口疮性口炎。>材料和方法:本研究招募了数百名诊断为复发性口疮性口炎的患者。将50名患者随机分配至两个治疗组中的每一个。在临床诊断和溃疡测量后,对每个受试者进行主观症状评估。两种药物均按指定间隔口服。在第一天进行溃疡测量和主观评估。>统计分析:使用曼恩·惠特尼(Mann Whitney)和t检验等各种测试进行分析。>结果与结论:平均发作次数,其值无统计学意义(p = 0.43),也不是平均溃疡数(p = 0.75),也不是平均溃疡大小(p = 0.91)。但是,总体结果表明,瑞巴派特的疗效与先前证实的左旋咪唑的疗效几乎相同。当前的研究为期三个月,包括疼痛高,口疮计数,溃疡大小和发生频率高的患者,在两个研究组中均显示出更好的结果。但是,建议瑞巴派特具有良好的耐受性,因此可能在治疗和预防不限于贝塞特氏病的反复发作的口疮中发挥作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号